Introduction: Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin use and subsequent changes in lipid parameters in patients with RA treated with intravenous or subcutaneous TCZ (TCZ-IV or TCZ-SC) over 2 years of treatment. Methods: Data were collected from patients with moderate to severe active RA who received C1 dose of the study drug in seven international, randomized, double-blind, controlled phase 3 and 4 clinical trials of TCZ-IV or TCZ-SC. Lipid levels and safety events were assessed over 2 years of treatment. Data were summarized for all pooled treatment groups of the intention-to-treat populations in the TCZ-IV and TCZ-SC studies, and results were stratified by concomitant statin use.
INTRODUCTION
Rheumatoid arthritis (RA) is a disease characterized by chronic inflammation and is associated with decreased survival compared with the general population [1] . This excess mortality in patients with RA is largely due to an increased risk of cardiovascular (CV) disease, although it remains unclear whether chronic inflammation, altered lipid levels, and/or traditional risk factors are the main drivers of the increased risk of CV events observed in RA [2] [3] [4] . In patients with RA, lipid levels appear to have a paradoxical relationship with CV disease risk [5] [6] [7] [8] . Whereas elevated lipid levels are typically associated with an increased risk of CV disease in the general population, lower lipid levels appear to be associated with an increased risk of CV disease in patients with RA [5] .
Evidence
suggests that reductions in time-averaged disease activity may decrease the risk of CV events [9] ; reductions in C-reactive protein in patients with RA may lead to improvements in high-density-lipoprotein cholesterol (HDL-C) efflux and increases in apolipoprotein AI, which may counteract any potential elevated CV risk because of concurrent increases in low-density-lipoprotein cholesterol (LDL-C) [10] . In addition, treatment with different classes of disease-modifying antirheumatic drugs (DMARDs) has demonstrated different directional changes in levels of lipid parameters and risk of CV disease; however, associations between treatment-induced alterations in lipid profiles and CV outcomes are unknown. For example, in patients with RA, treatment with tumor necrosis factor inhibitors has been shown to significantly increase HDL-C, total cholesterol (TC), and triglyceride (TG) levels without altering LDL-C levels, while treatment with the interleukin 6 receptor a inhibitor tocilizumab (TCZ) generally increases levels of all four of these parameters [11] . Another study found that treatment with tumor necrosis factor inhibitors was associated with decreased risk of CV events compared with conventional synthetic DMARD (csDMARD) use, but lipid levels were not assessed [12] . TCZ, a humanized monoclonal antibody that inhibits interleukin 6 receptor a, is approved as monotherapy or in combination with methotrexate for the treatment of patients with moderate to severe RA who have had an inadequate response to C1 csDMARD. TCZ has proven to be safe and efficacious when used in combination with csDMARDs or as monotherapy [13] [14] [15] [16] [17] [18] [19] [20] . Several clinical trials have investigated the effects of intravenous TCZ (TCZ-IV) or subcutaneous TCZ (TCZ-SC) therapy on lipid levels in patients with RA and generally found elevations in TC, LDL-C, HDL-C, and TGs by &12-16 weeks in patients treated with TCZ, which remained stable over time (Table S1 ) [13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . In addition, an integrated safety report from five randomized controlled trials and their long-term extension studies (AMBITION, RADIATE, TOWARD, OPTION, LITHE) demonstrated that lipid levels were elevated in the TCZ all-exposed population as early as 6 weeks after the first TCZ infusion and remained at these levels throughout 104 weeks of treatment [31] .
Another retrospective analysis examined the associations of baseline and on-treatment lipid levels, inflammation, and disease activity with risk of major adverse CV events in TCZ-treated patients pooled from five randomized controlled trials and their extension studies. This study found that changes in measures of RA disease activity, but not necessarily changes in lipids, were associated with an increased incidence of major adverse CV events in TCZ-treated patients [32] . Notably, TCZ doses as high as 20 mg/kg had no impact on LDL-C levels in healthy volunteers [33] . Whether these lipid elevations actually increase or decrease the risk of CV disease in TCZ-treated patients with RA is unclear; however, patients may benefit from treatment with lipid-lowering therapy, such as statins. The identification of potential statin-related adverse events (AEs) was initially evaluated in TCZ-treated patients who were or were not treated with concomitant statins at baseline, over 24 weeks using pooled data collected from five phase-3 clinical trials of TCZ-IV in patients diagnosed with moderate to severe RA according to the 1987 American College of Rheumatology classification criteria [34, 35] .
Overall, treatment with TCZ plus csDMARDs or as monotherapy resulted in increased mean LDL-C levels. The initial magnitude of the increase in mean LDL-C levels over the first 6 weeks was lower in TCZ-treated patients treated with concomitant statins from baseline than in the overall TCZ-treated population; the initiation of statin treatment post-baseline reduced mean LDL-C levels below baseline values in TCZ-treated patients. The original analysis included only studies of TCZ-IV. TCZ-SC is now approved; therefore, it is also important to evaluate TCZ-SC in patients with RA, especially to assess whether management of hyperlipidemia has evolved between the time of the initial pivotal trials of TCZ-IV and the more recent trial investigating TCZ-SC [18, 19] . The objectives of this post hoc analysis were to expand on the previous 24-week results by characterizing statin use in patients with RA who were treated with TCZ and to describe subsequent changes in lipid parameters stratified by concomitant baseline statin use, using data from seven different international phase 3 and 4 clinical trials with TCZ-IV and TCZ-SC treatment arms.
METHODS

Study Population
In this post hoc analysis, data were collected from patients who received C1 dose of study drug in seven international, multicenter, 
Clinical Assessments
Fasting lipid levels were assessed at baseline, 3-4, 6, 12 months, and 2 years; data were summarized for all pooled treatment groups of the intention-to-treat populations in the TCZ-IV and TCZ-SC studies. Demographic characteristics and inflammatory biomarker levels-including C-reactive protein, serum amyloid A, haptoglobin, and lipoprotein(a)were assessed at baseline. Notably, patients in the TCZ-IV treatment arms were followed for up to 5 years; however, due to the small numbers of patients at these longer time points, only the lipid level assessments from the first 2 years of follow-up were included in this analysis.
Guidelines for initiation of lipid-lowering therapy vary by study site locations; however, the decision to start a statin or other lipid-lowering drug was at the discretion of the investigator and not mandated by the individual study protocols (Table S2) . For this analysis, LDL-C C100 mg/dl or TC:HDL-C ratio [5 was used as a crude predictor of CV risk. To estimate whether statins were appropriately given in at-risk patients, we calculated the proportion of patients above each threshold who were on statins at each visit.
Selected AEs that were chosen post hoc as AEs that may, but not necessarily or causally, be related to statin use were assessed for up to 5 years during the individual studies and included musculoskeletal and connective tissue disorders, arthralgia, musculoskeletal pain, and myalgia. Serious CV events included all preferred terms in the Medical Dictionary for Regulatory Activities within the ''cardiac disorders'' and ''vascular disorders'' system organ classes.
Statistical Analysis
Descriptive statistics were used to summarize laboratory data, statin use, and AEs at each visit, and the results were stratified by concomitant statin use. All laboratory data were converted to the International System of Units and summarized with actual values and with the change from baseline over visits. Abnormal laboratory values were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events grading system (version 3) [36] . Shift tables summarized the proportion of patients at each visit with categorical shifts in lipid parameters from normal values at baseline (LDL-C \130 mg/dl; TC \240 mg/dl; HDL-C \60 mg/dl; TG \150 mg/dl) to the highest post-baseline values (LDL-C C130 mg/dl; TC C240 mg/dl; HDL-C C60 mg/dl; TG C150 mg/ dl).
All selected AEs and serious CV events were presented as event rates per 100 patient-years with 95% confidence intervals. No statistical imputation was performed for missing visits or incomplete data.
RESULTS
Baseline Characteristics
In this post hoc analysis, statin use and lipid Table 1 . Patients on statins at baseline in the TCZ-IV and TCZ-SC studies were generally older and weighed more compared with patients not treated with statins at baseline ( Table 1) . A higher proportion of patients on statins at baseline were male, had diabetes, had a family history of coronary heart disease, and had a history of hypertension and cardiac disorders compared with patients who were not treated with statins at baseline. These trends were similar in the TCZ-IV and TCZ-SC treatment groups ( Table 1) .
Description of Statin Use Over Time
In this post hoc analysis of 4655 patients, including 2616 patients (56.2%) with elevated LDL-C levels C100 mg/dl at baseline, 443 patients (9.5%) were on concomitant statins at baseline, 264 patients (5.9%) initiated statins post-baseline, and 3948 patients (84.8%) never initiated a statin during the study period.
Baseline statin use was comparable across all treatment groups (range 8.0-11.4%) ( Table S3 ). The most common lipid-lowering agents used at all time points were the lipophilic agents simvastatin and atorvastatin, with 3.2-4.6% of patients in each arm receiving simvastatin and 2.7-3.2% of patients receiving atorvastatin. Over time, statin use generally increased in the TCZ treatment groups and was three-to fourfold higher at 2 years (range 13.8-17.4%) compared with patients receiving csDMARD monotherapy (4.5%). Similar trends were generally observed for categorical shifts in TC, HDL-C, and TGs by treatment group and statin use ( Table 2) .
Analysis of Lipid Parameters
Evolution of LDL-C Over Time by Statin Use
Compared with patients who were never treated with statins, a smaller proportion of TCZ-treated patients (any formulation) who were on statins at baseline demonstrated shifts in TC and HDL-C from normal values (\240 and \60 mg/dl, respectively) at baseline to elevated levels (C240 and C60 mg/dl, respectively) through 6 months. This observation continued through 2 years for all treatment groups, except for the shift in TC in patients receiving TCZ-SC at 12 months and shifts in HDL-C in patients receiving TCZ-IV or TCZ-SC plus csDMARDs (observed through 12 months). Compared with patients who were never treated with statins, a larger proportion of patients receiving TCZ (IV or SC) plus csDMARDs demonstrated shifts in TGs from \150 mg/dl at baseline to C150 mg/dl through 2 years of follow-up. Statin use did not appear to have an appreciable effect on shifts from baseline in TC, HDL-C, or TGs for patients randomized to csDMARD monotherapy.
Proportion of Patients Treated with Statins by Elevated LDL-C Levels and TC:HDL-C Ratio
For this analysis, LDL-C C100 mg/dl was used to define patients who should be treated with lipid-lowering agents, regardless of whether they were prescribed one or not. The proportions of patients with LDL-C C100 mg/ dl at baseline who were treated with statins at baseline, 3-4, 6, 12 months, and 2 years are presented in Table 3 . Overall, &60% of patients across all studies had LDL-C C100 mg/dl at baseline: only 6.3-7.1% of patients in the TCZ-IV arms and 5.4% of patients in the csDMARD treatment arms were treated with statins. At 2 years, &78% of patients in the TCZ-IV arms had LDL-C C100 mg/dl; of these patients, only 11.0 and 13.3% of patients receiving TCZ-IV as monotherapy and combination therapy, respectively, were treated with statins. A higher proportion of TCZ-SC-treated patients with LDL C100 mg/dl at baseline were treated with statins at baseline (8.6%) than those in the TCZ-IV studies; however, overall, a high proportion of patients remained untreated. The proportion of patients receiving TCZ-SC with LDL-C C100 mg/dl who were also treated with statins generally increased over time; however, only 13.6% of patients were treated with statins despite having LDL-C C100 mg/dl at 2 years.
Similarly, the proportion of patients with TC:HDL-C [5 (above-average risk) who were treated with statins at any time point was low (Table 3 ). Approximately 5-10% of patients across all treatment groups had TC:HDL-C [5 at baseline; of these patients, 9.3 and 9.7% of Table 3 Proportion of patients with LDL-C C100 mg/dl and TC:HDL-C [5 who were treated with statins 
Safety
The rates of selected AEs and serious CV events by statin use are summarized in Table 4 . Of patients randomized to TCZ-IV 8 mg/kg q4w ? csDMARDs, those who were on concomitant statins at baseline had a higher rate of C1 musculoskeletal and connective However, despite these results, we also found that only a small proportion of patients who may be at a higher risk of CV disease (as estimated by LDL-C C100 mg/dl or TC:HDL-C [5) were treated with statins at any time point.
Because this was a descriptive post hoc analysis using pooled data, this study is not without some limitations. Notably, because a variety of different lipid-lowering agents were used, and at varying doses, it is difficult to ascertain the true effect of statins for the treatment groups that received concomitant statins at baseline or initiated statin treatment during the study. Similarly, it would be difficult however, there is no evidence to confirm that statin use had a causal relationship with any of these events. implementation of RA-specific guidelines on the recognition and management of elevated risk of CV events in patients with RA. this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Support for third-party writing assistance for this manuscript, furnished by Eric Deutsch, PhD, of Health Interactions, was provided by F.
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